anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The safety and effectiveness of SMOFlipid have been established as a source of calories and essential fatty acids for PN when oral or enteral nutrition is not possible, insufficient, or contraindicated in pediatric patients, including term and preterm neonates. Use of SMOFlipid in neonates is supported by evidence from short-term (i.e., 1- to 4- week) studies, and one study following neonates beyond 4 weeks [see Clinical Studies (14.2)]. Use of SMOFlipid in older pediatric patients is supported by evidence from a short-term (i.e., <28 days) study in pediatric patients 28 days to 12 years of age and additional evidence from studies in adults [see Clinical Studies (14)]. The most common adverse reactions in SMOFlipid-treated pediatric patients were anemia, vomiting, gamma-glutamyltransferase increased, and nosocomial infection [see Adverse Reactions (6.1)].

PNALD, also referred to as IFALD, has been reported in pediatric patients who received SMOFlipid for more than 2 weeks. PNAC (a precursor to PNALD) was reported less frequently in SMOFlipid- treated patients compared to soybean oil lipid emulsion-treated patients in Pediatric Study 1 [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]. Although clinically significant cases of EFAD were not observed during short-term use in pediatric clinical studies, cases of EFAD have been reported with the use of SMOFlipid in the postmarketing setting [see Warnings and Precautions (5.9), Adverse Reactions (6.1)]. Monitor pediatric patients for laboratory evidence of EFAD because they may be particularly vulnerable to neurologic complications if adequate amounts of essential fatty acids are not provided [see Warnings and Precautions (5.9)].

In the postmarketing setting, clinical decompensation with rapid infusion of intravenous lipid emulsion in neonates and infants, sometimes fatal, has been reported [see Warnings and Precautions (5.1)]. Because of immature renal function, preterm infants receiving prolonged treatment with SMOFlipid may be at risk for aluminum toxicity [see Warnings and Precautions (5.8)].
Stereotactic Ablative Radiotherapy (SABR) will be prescribed to a dose of 42Gy in 3 fractions. All radiotherapy treatment be completed within 3 weeks.Patients will undergo nephrectomy within 9-12 weeks after the first dose of treatment.
The novel positively charged non-steroidal anti-inflammatory drugs shown in general formulas (1, 2a, 2b, 2c or 2d), namely 'structural formulas 1, 2a, 2b, 2c or 2d', have been designed and synthesized. The compounds represented by the general formulas (1, 2a, 2b, 2c or 2d), namely 'structural formulas 1, 2a, 2b, 2c or 2d', can be prepared through reaction between the metal salts, organic alkali salts or immobilized alkali salts of the non-steroidal anti-inflammatory drugs and appropriate halides. The positively charged amino in a prodrug of the invention greatly improves the solubility of the drugs in water and can further combine with negative charges on the phosphate terminal groups of a biological membrane. Thus, the local concentrations of the drugs on the biological membrane or the outer side of the skin are very high so as to facilitate the diffusion of the prodrugs from high-concentration areas to low-concentration areas. The biological membrane can be slightly disturbed through the combination so as to allow parts of space for the fat soluble parts of the prodrugs. When molecules of the biological membrane move, the biological membrane is slightly squeezed due to the combination effects of the prodrugs, and when the amino is not protonized, the amino in the prodrugs is separated from the phosphate terminal groups of the biological membrane, and the prodrugs completely penetrate into the biological membrane. When the amino in the prodrugs moves to the other side of the biological membrane and therefore the amino is protonized, the prodrugs are drawn into the cytoplasm, a half-liquid-state aqueous solution or a suspension solution. The prodrugs can be used for the treatment and prevention of diabetes mellitus (type I and/or type II), pathoglycemia and dyslipidemia, apoplexia, myocardial infarction and other cardiac and cardiovascular diseases, an Alzheimer's disease, a Parkinson's disease and other neurodegenerative diseases, psoriasis, discoid lupus erythematosus, systemic lupus erythematosus (SLE), autoimmune hepatitis, multiple sclerosis (MS) and other autoimmune diseases, amyotrophic lateral sclerosis (ALS), oculopharyngeal muscular dystrophy (OPMD) and other muscle abnormalities, inflamed hemorrhoids, cryptitis and other anorectal inflammatory conditions, pruritus ani, prostatitis, prostatocystitis, varicose veins, autoimmune hepatitis, autoimmune nephritis, phlebitis and other inflammations, skin cancers, breast cancers, colon-rectal cancers, oral cancers and other cancers, scars, abnormal cutaneous vascular lesions, birthmarks and pigmented naevus (pigment), and the prodrugs can directly perform cutaneous penetration without skin permeation promoters.
In this study, we present the first meta-analysis of human urine reported in the literature, drawing data from a total of 35 articles with a combined participant count of 14,021. Through this analysis, we have developed an artificial urine (AU) composition that can be adjusted within typical physiological parameters for in vitro applications. Our findings demonstrate the utility of this AU in determining the solubility of nitrofurantoin, particularly in the context of crystalluria. Notably, we observe that in saline, nitrofurantoin solubility, within the framework of its urinary pharmacokinetics, suggests a risk of crystalluria. However, in AU, this risk is mitigated due to complexation with urea. More broadly, we anticipate that our developed formulation will serve as a foundation for translational studies across biomedical and pharmaceutical sciences.
BACKGROUND: Congenital cytomegalovirus (cCMV) infection, resulting from non-primary maternal infection or reactivation during pregnancy, can cause serious fetal abnormalities, complications in the immediate neonatal period, and severe sequelae later in childhood. Maternal non-primary cytomegalovirus infection in pregnancy is transmitted to the fetus in 0.5-2% of cases (1).
CASE PRESENTATION: An African full term male newbornwas delivered by emergency caesarean section. Due to signs of asphyxia at birth and clinical moderate encephalopathy, he underwent therapeutic hypothermia. Continuous full video-electroencephalography monitoring showed no seizures during the first 72 h, however, soon after rewarming, he presented refractory status epilepticus due to an intracranial hemorrhage, related to severe thrombocytopenia. The patient also presented signs of sepsis (hypotension and signs of reduced perfusions). An echocardiography revealed severe cardiac failure with an ejection fraction of 33% and signs suggestive of cardiomyopathy. Research for CMV DNA Polymerase Chain Reaction (PCR) on urine, blood, cerebrospinal fluid, and nasopharyngeal secretions was positive.The mother had positive CMV IgG with negative IgM shortly before pregnancy. Serology for CMV was therefore not repeated during pregnancy, but CMV DNA performed on the Guthrie bloodspot taken at birth yielded a positive result, confirming the intrauterine transmission and congenital origin of the infection. The baby was discharged in good general condition and follow up showed a normal neurodevelopmental outcome at 9 months.
CONCLUSION: Although uncommon, congenital cytomegalovirus infection should be included in the differential diagnosis of intraventricular hemorrhage and cardiomyopathy. Furthermore, this case highlights the possible severity of congenital cytomegalovirus infection, even in cases of previous maternal immunity.
Subjects randomized to receive the medications will receive acetylcysteine and dornase alfa, two medications frequently used in the treatment of atelectasis. The medications will alternate every 6 hours for 48 hours.
Participants receive the HEAL antimicrobial solution for 2 hours once daily for a minimum of 5 consecutive days. Participants also receive the lock therapy once weekly for two additional weeks. Principle ingredients include minocycline, calcium disodium ethylenediaminetetraacetate (CaEDTA) and ethanol.
Oligodeoxynucleotides containing CpG motifs (CpG-ODN) can promote antimicrobial immunity in chickens by enriching immune compartments and activating immune cells. Innate memory, or trained immunity, has been demonstrated in humans and mice, featuring the absence of specificity to the initial stimulus and subsequently cross-protection against pathogens. We hypothesize that CpG-ODN can induce trained immunity in chickens. We delivered single or multiple administrations of CpG-ODN to birds and mitochondrial oxidative phosphorylation (OXPHOS) and glycolysis of peripheral blood mononuclear cells were quantified using Seahorse XFp. Next, chickens were administered with CpG-ODN twice at 1 and 4 day of age and challenged with Escherichia coli at 27 days of age. The CpG-ODN administered groups had significantly higher mitochondrial OXPHOS until 21 days of age while cellular glycolysis gradually declined by 14 days of age. The group administered with CpG-ODN twice at 1 and 4 days of age had significantly higher survival, lower clinical score and bacterial load following challenge with E. coli at 27 d of age. This study demonstrated the induction of trained immunity in broiler chickens following administration of CpG-ODN twice during the first 4 days of age to protect birds against E. coli septicemia at 27 days of age.
The present invention provides a method for the prevention and treatment of viral-induced tumors, more specifically, human warts. The method uses sandalwood oil and/or derivatives from the sandalwood oil to prepare medicaments for the prevention and treatment of viral-induced tumors (i.e., warts caused by the human papillomavirus (HPV)) in humans. The method of the invention comprises the topical administration of the sandalwood oil or a composition derived therefrom to the human epidermis and/or to the genital tract as needed. The present invention is also concerned with a unique antiviral composition useful for topical application. The antiviral composition according to this invention is also effective against other DNA viruses such as the DNA pox virus that causes Molluscum contagiosum and may be effective against other DNA viruses such as AIDS virus and RNA viruses. The sandalwood oil compositions are also effective against genital warts and HPV of the genital tract and will prevent cancer of the skin and cervix.
A machine learning engine is presented. The disclosed recommendation engine generates an ensemble of trained machine learning models that are trained on known genomic data sets and corresponding known clinical outcome data sets. Each model can be characterized according to its performance metric or other attributes describing the nature of the trained model. The attributes of the models can also relate to one or more potential research projects, possibly including drug response studies, drug or compound research, types of data to collect, or other topics. The potential research projects can be ranked according to the performance or characteristic metrics of models that share common attributes with the potential research projects. Projects having high rankings according to the model metrics are considered as targeting that would likely be most insightful. Fig. 1
Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Patients will have the option to crossover to the combination arm based upon the pre-clinical data.
INTRODUCTION: Nutrition and physical activity are two major issues in the management of CKD patients who are often older, have comorbidities, and are prone to malnutrition and physical inactivity, conditions that cause loss of quality of life and increase the risk of death. We performed a multidimensional assessment of nutritional status and of physical performance and activity in CKD patients on conservative therapy in order to assess the prevalence of sedentary behavior and its relationship with body composition.
METHODS: A total of 115 consecutive stable CKD patients aged 45-80 years were included in the study. They had no major skeletal, muscular, or neurological disabilities. All patients underwent a multidimensional assessment of body composition, physical activity, and exercise capacity.
RESULTS: Sedentary patients, as defined by mean daily METs <1.5, were older and differed from non-sedentary patients in terms of body composition, exercise capacity, and nutrient intake, even after adjusting for age. Average daily METs were positively associated with lean body mass, muscle strength, 6MWT performance but negatively associated with fat body mass, body mass index, and waist circumference. In addition, a sedentary lifestyle may have negative effects on free fat mass, muscle strength, and exercise capacity and may increase fat body mass. Conversely, decrease in muscle mass and/or an increase in fat mass may lead to a decrease in physical activity and exercise capacity.
CONCLUSION: There is a clear association and potential interrelationship between nutritional aspects and exercise capacity in older adults with CKD: they are really the two sides of the same coin.
NEW MATERIAL:The compound shown by the formula I [Y is 0, -(CH2)m-; m is 0 or 1; n is 1 or 2; R1-3 are H, lower alkyl, halogen, etc.; R4 is lower alkyl, a group shown by the formula II, etc.] and its acid addition salt. EXAMPLE:2-Methyl-2-azaerythrinan. USE:A drug. Having depressing action of central nervous system, especially strong pain-killing action. PROCESS:A compound shown by the formula III (R6 is alkyl) is condensed with a compound shown by the formula IV under heating, and subjected to ring closure under acidic conditions, to give a compound shown by the formula V. The lactam ring of the compound shown by the formula V is then reduced with lithium aluminum hydride, boran, etc., to give a compound shown by the formula I.
BACKGROUND: Chemokine ligands and their corresponding receptors are essential for regulating inflammatory responses. Chemokine receptors can stimulate immune activation or inhibit/promote signaling pathways by binding to specific chemokine ligands. Among these receptors, CC chemokine receptor 1 (CCR1) is extensively studied as a G protein-linked receptor target, predominantly expressed in various leukocytes, and is considered a promising target for anti-inflammatory therapy. Furthermore, CCR1 is essential for monocyte extravasation and transportation in inflammatory conditions. Its involvement in inflammatory diseases of the central nervous system (CNS), including multiple sclerosis, Alzheimer's disease, and stroke, has been extensively studied along with its ligands. Animal models have demonstrated the beneficial effects resulting from inhibiting CCR1 or its ligands.
SUMMARY: This review demonstrates the significance of CCR1 in CNS inflammatory diseases, the molecules implicated in the inflammatory pathway, and potential drugs or molecules for treating CNS diseases. This evidence may offer new targets or strategies for treating inflammatory CNS diseases.
Groups 2 will be HIV-1-infected. The first visit of individuals in groups 2 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
Mycophenolate mofetil is an antimetabolite immunosuppressant. It is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent; inosine monophosphate dehydrogenase (IMPDH) inhibitor.

The chemical name for mycophenolate mofetil (MMF) is 2-morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate. It has an empirical formula of C23H31NO7, a molecular weight of 433.50, and the following structural formula: 

MMF is a white or almost white crystalline powder. It is practically insoluble in water, freely soluble in acetone, sparingly soluble in anhydrous ethanol. The apparent partition coefficient in 1-octanol/water (pH 7.4) buffer solution is 238. The pKa values for MMF are 5.6 for the morpholino group and 8.5 for the phenolic group. 

Mycophenolate mofetil is available for oral administration as a powder for oral suspension which, when reconstituted, contains 200 mg/mL of MMF. 

Inactive ingredients in mycophenolate mofetil for oral suspension, USP include aspartame, citric acid anhydrous, colloidal silicon dioxide, methylparaben, natural and artificial gum fruit flavor, sorbitol, soybean lecithin, tri-sodium citrate dihydrate and xanthan gum.

FDA approved dissolution specification differs from the USP dissolution specification.
There has been no data on effect of Bifidobacterium breve on symptoms of patients with irritable bowel syndrome (IBS). We hypothesized that Bifidobacterium breve is effective on symptoms of IBS patients. IBS patients will be enrolled via advertisement. Any IBS subtypes will not be rejected. They will take either 1.0 g of Bifidobacterium breve 3 times a day or same amount of placebo for 8 weeks. IBS symptoms and allied markers will be checked before, during, and after the administration.
A bolus for ruminant animals is an eroding, leaching or composite bolus and is partially or completely coated with a material which is insoluble or sparingly soluble in water. In use, the coating is progressively removed from the bolus by abrasion by the reticulo-rumen and its contents. The coating may comprise two or more materials differing in resistance to abrasion, applied to different parts of the bolus. The coating maybe of uniform thickness or of different thicknesses over parts of the bolus. The coating may comprise one or more waxes which may be hard or soft waxes, such as vegetable (e.g. carnauba wax) or beeswax and may be applied by dipping in the melted wax. The coating may be applied in two stages comprising applying an initial coat and heating the bolus ready for application of a second coat.
Glycosaminoglycans (GAGs) are important biopolymers that differ in the sequence of saccharide units, and in post-polymerization alterations at various positions, making these molecules complex and challenging to analyse. We have developed an approach that enables small quantities (< 200 ng) of hundreds of different GAGs to be analysed within a short time frame (3-4 hours). Time of flight secondary ions mass spectrometry 10 together with multivariate analysis was used to analyse an array of over 400 GAG samples. Resultant spectra were derived from the whole molecules and did not require pre-digestion. All 6 GAG types were successfully discriminated, both alone and in the presence of fibronectin. We also distinguished between pharmaceutical grade heparin derived from different animal species and from different suppliers to a sensitivity as 15 low as 0.001 wt%. This approach is highly beneficial in the quality control of GAGs produced for therapeutic applications and for characterising GAGs within biomaterials or from in vitro cell culture.
Falls are a serious health issue and are the greatest cause of death in the elderly. The use of the music of Nolwenn Leroy in fall prevention has been reported at a major scientific meeting "Posturographic Changes and Fall Prevention associated with Music Therapy: The Nolwenn Effect (USA ClinicalTrials.gov Identifier: NCT00121693) featured at the 7th Annual American Music Therapy Association Conference in Orlando, Florida, Nov 15-20, 2005 and Decreasing falls in a geriatric nursing home setting is associated with the saving of lives. Another similar study (USA ClinicalTrials.gov Identifier:NCT00272272)is presently being conducted in a geriatric nursing home facility in Georgia. We propose the utilization of the Nolwenn Effect in our resident geriatric population at several Dallas, Texas Geriatric Nursing Home Facilities and comparing fall rates to those we have carefully recorded in the past. We will obtain computerized dynamic posturographic measurements utilizing the CAPS posturographic unit by Vestibular Technologies on all residents of several Dallas Geriatric Nursing Facilities. Our findings will be compared to normative data previously validated to represent a probability of falling. Daily listening to selections from Nolwenn Leroy's CD "Nolwenn" will be played each morning (daily) over the address system throughout the nursing home for approximately 5-10 minutes. Repeat CAPS tests will be obtained one week after the initiation of the study and at monthly intervals over a 12 month period of time. We propose to compare the posturographic data and the rate of falls recorded in the nursing homes to previously established fall data for the institutions. Preliminary observations have been associated with a decrease rate of falls in the geriatric nursing home environment when listening to the music of Nolwenn Leroy. The incorporation of these statistics will allow us to investigate a cost effective method of reducing falls that might save lives, evoke societal change and act as a model for other Geriatric Nursing Home settings. The objective measurements with the CAPS will allow us to further compare the incidence of falls with a probability of fall measurements.
The invention provides a manufacturing method of anthypnotic wet tissue. During pulping, 2-5wt% wet strength agent and 1-2wt% softener are added, a large roll of toilet paper can be produced by the conventional paper-making process and, is subjected to back-rolled and is cut into small rolls. The paper is soaked in an anthypnotic liquid medicine so thatto enable that the water content is in a range of 40-100% and packaged tightly to form the product. The anthypnotic liquid medicine consists of components A and B. The component A is prepared by dissolving 6-12 parts of oleum menthae, 2-4 parts of wintergreen oil, 4-12 parts of menthol, 4-8 parts of camphor, 2-6 parts of borneol, 5-10 parts of ginger extract, 1-2 parts of clove oil and 1-3 parts of eucalypus oil in 100-400 parts of ethanol, and adding 5-20 parts of emulsifier. The component B is prepared by dissolving 20-100 parts of glycerol, 20-200 parts of propylene glycol, and 0.5-5 parts of acetic chlorhexidine in 500 parts of water. The product is flexible in texture and good in toughness, and can be used as anthypnotic and refreshing healthcare facial tissue.